Securities Purchase AgreementSecurities Purchase Agreement • December 23rd, 2022 • China SXT Pharmaceuticals, Inc. • Pharmaceutical preparations • Utah
This Securities Purchase Agreement (this “Agreement”), dated as of December 19, 2022, is entered into by and between China SXT Pharmaceuticals, Inc., a British Virgin Islands corporation (“Company”), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”).
CONVERTIBLE PROMISSORY NOTEConvertible Promissory Note • December 23rd, 2022 • China SXT Pharmaceuticals, Inc. • Pharmaceutical preparations • Utah
This Note carries an OID of $95,000.00 all of which amount is fully earned as of the Effective Date and included in the initial principal balance. In addition, Borrower agrees to pay $20,000.00 to Lender to cover Lender’s legal fees, accounting costs, due diligence, monitoring and other transaction costs incurred in connection with the purchase and sale of this Note (the “Transaction Expense Amount”), which amount will be deducted from the amount funded. The purchase price for this Note shall be $1,500,000.00 (the “Purchase Price”), computed as follows: $1,595,000.00 original principal balance, less the OID. The Purchase Price shall be payable by Lender by wire transfer of immediately available funds.
